Letter to the Editor regarding "Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgery".
作者信息
Aphale Parth, Shekhar Himanshu, Dokania Shashank
机构信息
D.Y. Patil Vidyapeeth (Deemed to be University), Pimpri, Pune, Maharashtra, India.
出版信息
Am Heart J Plus. 2025 Aug 14;58:100591. doi: 10.1016/j.ahjo.2025.100591. eCollection 2025 Oct.
Abstract
摘要
相似文献
1
Letter to the Editor regarding "Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgery".致编辑的信：关于“冠状动脉搭桥手术后添加终身低剂量秋水仙碱作为二级预防的临床益处和成本效益”
Am Heart J Plus. 2025 Aug 14;58:100591. doi: 10.1016/j.ahjo.2025.100591. eCollection 2025 Oct.
2
Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgery.冠状动脉搭桥手术后添加终身低剂量秋水仙碱作为二级预防的临床益处和成本效益。
Am Heart J Plus. 2025 Jul 16;57:100580. doi: 10.1016/j.ahjo.2025.100580. eCollection 2025 Sep.
3
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤：系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
4
A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era.药物洗脱支架时代经皮冠状动脉介入治疗与手术治疗多支血管病变的成本效果系统评价。
Eur Heart J Qual Care Clin Outcomes. 2016 Oct 1;2(4):261-270. doi: 10.1093/ehjqcco/qcw007.
5
Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery).用于冠状动脉搭桥术（伴或不伴瓣膜手术）的远程缺血预处理
Cochrane Database Syst Rev. 2017 May 5;5(5):CD011719. doi: 10.1002/14651858.CD011719.pub3.
6
Inhalation versus intravenous anaesthesia for adults undergoing on-pump or off-pump coronary artery bypass grafting: A systematic review and meta-analysis of randomized controlled trials.接受体外循环或非体外循环冠状动脉搭桥术的成人患者吸入麻醉与静脉麻醉的比较：一项随机对照试验的系统评价和荟萃分析
J Clin Anesth. 2017 Aug;40:127-138. doi: 10.1016/j.jclinane.2017.05.010.
7
New-generation stents compared with coronary bypass surgery for unprotected left main disease: A word of caution.新一代支架与冠状动脉旁路移植术治疗无保护左主干病变的比较：需谨慎对待。
J Thorac Cardiovasc Surg. 2018 May;155(5):2013-2019.e16. doi: 10.1016/j.jtcvs.2017.11.066. Epub 2018 Jan 12.
8
Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease.64层及以上计算机断层扫描血管造影术作为冠状动脉疾病检查中侵入性冠状动脉造影替代方法的临床有效性和成本效益的系统评价。
Health Technol Assess. 2008 May;12(17):iii-iv, ix-143. doi: 10.3310/hta12170.
9
Paediatric coronary artery bypass grafting in a middle-income country: a case series and literature review.中等收入国家的小儿冠状动脉搭桥术：病例系列及文献综述
Cardiol Young. 2025 Jul;35(7):1415-1420. doi: 10.1017/S1047951125101285. Epub 2025 Aug 1.
10
Ischemic Mitral Valve Regurgitation in Patients Undergoing Coronary Artery Bypass Grafting-Early and Late-Term Outcomes of Surgical Treatment.接受冠状动脉旁路移植术患者的缺血性二尖瓣反流——外科治疗的早期和晚期结果
J Clin Med. 2025 Jul 9;14(14):4855. doi: 10.3390/jcm14144855.
本文引用的文献
1
Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgery.冠状动脉搭桥手术后添加终身低剂量秋水仙碱作为二级预防的临床益处和成本效益。
Am Heart J Plus. 2025 Jul 16;57:100580. doi: 10.1016/j.ahjo.2025.100580. eCollection 2025 Sep.
2
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.慢性冠状动脉疾病患者服用小剂量秋水仙碱的个体终生获益。
Eur J Prev Cardiol. 2023 Dec 21;30(18):1950-1962. doi: 10.1093/eurjpc/zwad221.
3
Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events.秋水仙碱对复发性心血管事件的成本效益分析
CJC Open. 2023 Feb 24;5(5):348-356. doi: 10.1016/j.cjco.2023.02.005. eCollection 2023 May.
4
Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials.冠心病患者使用秋水仙碱：随机试验的系统评价与荟萃分析
J Am Heart Assoc. 2021 Aug 17;10(16):e021198. doi: 10.1161/JAHA.121.021198. Epub 2021 Aug 7.
5
Colchicine in Patients with Chronic Coronary Disease.秋水仙碱治疗慢性冠心病
N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
Zotero 插件